TORONTO, March 26 /CNW/ - GT Canada Medical Properties Inc. ("GT Canada"), a company listed on the TSX Venture Exchange (the "Exchange"), is pleased to announce that the Exchange has issued a bulletin announcing final acceptance of GT Canada's qualifying transaction. Trading in the common shares of GT Canada on the Exchange is scheduled to commence on Monday, March 29, 2010, under the symbol "MOB".
As Canada's first publicly-traded company focused exclusively on medical office properties, GT Canada's goal will be to increase shareholder value by becoming the leading owner and developer of these assets in Canada through an aggressive acquisition and development program aimed at creating a geographically diversified portfolio of high quality properties that will generate stable and growing rental income and capital appreciation opportunities. GT Canada plans to identify a significant pipeline of acquisition opportunities and begin pursuing these immediately with a view to significantly expanding its property portfolio over the short to medium term.
This news release contains "forward-looking statements" within the meaning of applicable securities laws. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that GT Canada may not be able to acquire or develop assets on favourable terms, or at all. The statements in this news release are made as of the date of this release. The factors identified above are not intended to represent a complete list of the factors that could affect GT Canada. Additional factors are noted under "Risk Factors" in GT Canada's Information Circular dated November 9, 2009, a copy of which may be obtained on the SEDAR website at www.sedar.com.
The TSX Venture Exchange Inc. has neither approved nor disapproved of the contents of this press release.
SOURCE GT CANADA MEDICAL PROPERTIES INC.
For further information: For further information: Andrew Shapack, Chief Executive Officer, GT Canada Medical Properties Inc., (416) 572-2170